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Background: Hereditary angioedema (HAE) caused by deficiency (type I) or dysfunction 
(type II) of the C1 inhibitor protein (C1-INH-HAE) is a disabling, potentially fatal condition 
characterized by recurrent episodes of swelling. We have recently found that patients 
with C1-INH-HAE have increased plasma levels of vascular endothelial growth factors 
and angiopoietins (Angs), which have been associated with vascular permeability in 
several diseases. Among these and other factors, blood endothelial cells and vascular 
permeability can be modulated by extracellular or secreted phospholipases A2 (sPLA2s).
Objective: We sought to investigate the enzymatic activity and biological functions of 
sPLA2 in patients with C1-INH-HAE.
Methods: sPLA2s enzymatic activity was evaluated in the plasma from 109 adult patients 
with C1-INH-HAE and 68 healthy donors in symptom-free period and attacks. Plasma 
level of group IIA sPLA2 (hGIIA) protein was measured in selected samples. The effect of 
C1-INH-HAE plasma on endothelial permeability was examined in vitro using a vascular 
permeability assay. The role of hGIIA was determined using highly specific sPLA2 indole 
inhibitors. The effect of recombinant hGIIA on C1-INH activity was examined in vitro by 
functional assay.
results: Plasma sPLA2 activity and hGIIA levels are increased in symptom-free C1-INH-
HAE patients compared with controls. sPLA2 activity negatively correlates with C1-INH 
protein level and function. C1-INH-HAE plasma increases endothelial permeability 
in vitro, and this effect is partially reverted by a specific hGIIA enzymatic inhibitor. Finally, 
recombinant hGIIA inhibits C1-INH activity in vitro.
Abbreviations: Angs, angiopoietins; BK, bradykinin; BAEC, bovine aortic endothelial cells; CRP, C reactive protein; C1-INH-
HAE, hereditary angioedema due to C1-inhibitor deficiency; HSPGs, heparan sulfate proteoglycans; HK, high-molecular 
weight kininogen; RFU, relative fluorescent unit; sPLA2s, secreted phospholipases A2; hGIIA, human sPLA2 group IIA; VEGFs, 
vascular endothelial growth factors.
TaBle 1 | Characteristics of 109 patients with C1-INH-HAE and 68 healthy 
donor controls.
characteristics healthy donors (n = 68) Patients (n = 109)
Age—yearsa 32 (28–40) 37 (23–48)
Gender male—no. (%) 32 (47%) 38 (34.9%)
Caucasian race—% 100% 100%
Unrelated families NA 76
Age at onset—yearsa NA 6 (3–14)
C1-INH-HAE—no. (%)
Type I NA 104 (95.4%)
Type II NA 5 (4.5%)
Prophylaxis—no. (%)
Tranexamic acid NA 4 (3.8%)
Attenuated androgens NA 15 (10%)
≥12 attacks/year—no. (%) NA 40 (36.7%)
aData are expressed as median values (interquartile ranges). Data were analyzed  
by t-test.
NA, not applicable.
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conclusion: sPLA2 enzymatic activity (likely attributable to hGIIA), which is increased in 
C1-INH-HAE patients, can promote vascular permeability and impairs C1-INH activity. 
Our results may pave the way for investigating the functions of sPLA2s (in particular, 
hGIIA) in the pathophysiology of C1-INH-HAE and may inform the development of new 
therapeutic targets.
Keywords: hereditary angioedema, angiogenesis, angiopoietins, c1 inhibitor deficiency, vascular endothelial 
growth factor, vascular permeability, phospholipase a2
inTrODUcTiOn
Hereditary angioedema due to C1-inhibitor deficiency (C1-INH- 
HAE) is a disabling, potentially fatal condition characterized 
by recurrent episodes of swelling caused by reduced levels 
(type I) or dysfunction (type II) of the C1-INH protein (1, 2). 
These patients display insufficient C1-INH function to prevent 
bradykinin (BK) formation (3), which increases endothelial 
permeability and leads to recurrent episodes of swelling 
(i.e., angioedema attacks) involving the deeper layers of the 
skin and/or submucosal tissue (4–6). High concentrations of 
circulating BK and cleaved high-molecular weight kininogen 
(HK) are elevated in patients with C1-INH-HAE and further 
increased during angioedema attacks, with the latter correlating 
with attack frequency (7, 8). In addition, specific BK antago-
nism reverts angioedema symptoms (9). Even if, BK stands as 
main mediator of C1-INH-HAE (10, 11), the need to explain 
symptom variability among patients genetically deficient in 
C1-INH prompt on identifying additional factors that modulate 
endothelial cell biology and vascular permeability (12).
Vascular endothelial growth factors (VEGFs) and angio-
poietins (Angs) have well-established role in endothelial cells 
conditioning and modulation of permeability (13–16) and 
we recently showed their increase in plasma of patients with 
C1-INH-HAE in symptom-free period (17). Interestingly, 
variants in angiopoietins 1 gene (ANGPT1) are associated with 
a recently described form of hereditary angioedema (HAE) (18). 
Nevertheless, other factors controlling endothelial cell biology 
and vascular permeability may intervene in C1-INH-HAE.
Phospholipase A2 (PLA2) enzymes hydrolyze the fatty acid 
from membrane glycerophospholipids releasing arachidonic 
acid, and lysophospholipid (19, 20). The superfamily of PLA2 
comprises different proteins that can be divided into six classes 
(20, 21). Secreted or extracellular PLA2s (sPLA2s) directly modu-
lates endothelial cell migration and vascular permeability in vitro. 
The effects of sPLA2s depend on their enzymatic acti vity and 
ability to engage different targets [e.g., PLA2R1, heparan sulfate 
proteoglycans (HSPGs), integrins] (22–31). They play critical 
roles in several pathophysiological processes. Indeed, sPLA2s 
activate several immune cell subsets (25, 30–33) and are expressed 
in inflamed tissues and tumors (19, 20, 34, 35).
Owing to the ability of sPLA2s to modulate vascular per-
meability (either by directly activating endothelial cells or by 
catalyzing the production/degradation of vasoactive molecules) 
(36), we have analyzed the enzymatic activity and biological 
function of sPLA2s present in plasma from C1-INH-HAE 
patients in symptom-free period and during attacks.
MaTerials anD MeThODs
reagents
The following were purchased: bovine aortic endothelial cells 
(BAEC) (Thermo Fisher Scientific©, San Jose, CA, USA); bovine 
serum albumin, l-glutamine, antibiotic–antimycotic solution 
(10,000 IU/ml penicillin, 10 mg/ml streptomycin, and 25 µg/ml 
amphotericin B), Heparinase I and III Blend from Flavobacte­
rium heparinum, DMEM and fetal calf serum (endotoxin 
level <0.1 EU/ml) (MP Biomedicals Europe, Illkirch, France). 
Antibody anti-VEGF-A, anti-Ang1, and anti-Ang2 (R&D System, 
Minneapolis, MN, USA). The recombinant human secreted 
phospholipase A2 group IIA (hGIIA) was prepared as described 
(37) and the inhi bitor Me-Indoxam (38) and RO032107A (39) 
were obtained from Dr. Michael Gelb (University of Washington, 
Seattle, WA, USA). All other reagents were from Carlo Erba 
(Milan, Italy).
study Population
We studied 109 C1-INH-HAE patients followed at the University 
of Milan, University of Naples Federico II, and University of 
Budapest and 68 normal healthy controls. Diagnosis of C1-INH-
HAE was based on the presence of at least one clinical and 
labo ratory criteria as described (40). Table  1 summarizes the 
clinical characteristics of patients with C1-INH-HAE and healthy 
controls. Patients (104 type I and 5 type II C1-INH-HAE) belong 
to 76 unrelated families and their median age at symptoms onset 
was 6 years (interquartile range 3–14). There were no differences 
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between the study groups in terms of age, sex, and ethnicity. The 
frequency of angioedema attacks was used as an index of disease 
severity; therefore, patients were grouped according to the num-
ber of attacks registered during the last 12 months: 69 of them 
had less than 12 attacks (low frequency), while 40 complained 
≥12 attacks (high frequency). Regarding symptom-free samples, 
blood sampling was performed at least 8  days apart from an 
angioedema attack in all patients. In 22 patients, blood samples 
were obtained also during angioedema attack. Nineteen patients 
were taking prophylactic therapy at the time of blood collection 
(4 were on tranexamic acid and 15 on attenuated androgens).
Blood sampling
The Ethical Committee of the University of Naples Federico II, 
University of Milan, and University of Budapest approved that 
plasma obtained during routine diagnostics could be used for 
research investigating the physiopathology of HAE and writ-
ten informed consent was obtained from patients according to 
the principles expressed in the Declaration of Helsinki. Blood 
was collected during routine diagnostic procedures and the 
remaining plasma sample was labeled with a code which was 
documented into a datasheet. The controls had been referred 
for routine medical check-up and volunteered for the study by 
giving informed consent. Technicians who performed the assays 
were blinded to the patients’ history. Blood was drawn by a clean 
venepuncture and minimal stasis using two types of anticoagu-
lants: sodium citrate 3.2% and, for the measurement of cleaved 
HK, an inhibitor cocktail containing 100  mM benzamidine, 
400 µg/ml hexadimethrine bromide, 2 mg/ml soybean trypsin 
inhibitor, 263  µM leupeptin, and 20  mM aminoethylbenzene-
sulphonyl fluoride dissolved in acid/citrate/dextrose (100  mM 
trisodium citrate, 67 mM citric acid, and 2% dextrose, pH 4.5). 
After centrifugation (2,000 g for 20 min at 22°), the plasma was 
divided into aliquots and stored at −80°C until used.
complement system analysis
Tube with an anti-coagulant sodium citrate 3.2% is used for 
separating plasma from whole blood. Plasma C1-INH was 
measured by radial immunodiffusion (NOR-Partigen, Siemens 
Healthcare Diagnostics, Munich, Germany). C4 antigen levels in 
Italia was measured by radial immunodiffusion (NOR-Partigen) 
(the method is not specific for C4 fragments) whereas in Hungary 
C4 levels was measured by turbidimetry (Roche Cobas Integra 
800, Beckman Coulter Complement C4). The antibody employed 
in the Beckman Coulter C4 assay is directed against the common 
portion of the C4 molecule and it exhibit the same reactivity 
with C4 fragments as well as with the native molecule.
C1-INH function was assessed as the capacity of plasma to 
inhibit the esterase activity of exogenous C1s as measured on a spe-
cific chromogenic substrate by means of a commercially available 
kit (Technoclone GmbH, Vienna, Austria) (17). Reference ranges 
were 0.70–1.30 U C1-INH/ml (1 U C1-INH corresponds to the 
average C1-INH activity present in 1 ml of fresh citrated normal 
plasma). The functional activity of C1-INH was also expressed as 
a percentage of activity of C1-INH present in samples. Normal 
values of activity of C1-INH are greater than 0.7 U C1 INH/ml 
(>70%). According to diagnostic criteria, all patients enrolled 
in this study had C1-INH functional activity lower than 50% of 
normal (41). In selected experiments, plasma of healthy controls 
was incubated (2 h, 37°C) with and without hGIIA (0.5–5 µg/ml). 
After treatment, enzymatic activity of C1-inhibitor was assessed 
using commercially available MicroVue C1-Inhibitor EIA kit 
(Quidel, San Diego, CA, USA).
Determination of VegFs and angs
Plasma levels of angiogenic and lymphangiogenic mediators were 
measured using commercially available ELISA kits for VEGF-A, 
VEGF-C, Ang1, and Ang2 (R&D System, Minneapolis, MN, USA) 
according to the manufacturer’s instructions (17). The ELISA 
sensitivity is 31.1–2,000 pg/ml for VEGF-A, 62–4,000 pg/ml for 
VEGF-C, 156.25–10,000 pg/ml for Ang1, and 31.1–4,000 pg/ml 
for Ang2.
contact system analysis
The cleavage of HK was assessed by means of sodium dodecyl sulfate- 
polyacrylamide gel electrophoresis (SDS-PAGE) and immuno -
blotting analysis (a modification of the method descri bed by 
Berrettini et al.) (42). Samples were loaded on a 9% SDS-PAGE. 
After electrophoretic separation, proteins were transferred from 
the gel to a polyvinylidene difluoride membrane using Bio-Rad 
Trans-Blot® Turbo™ Transfer System (Bio-Rad Laboratories, 
Hercules, CA, USA). HK was identified using goat polyclonal anti-
HK light chain (Nordic, Tilburg, The Netherlands) and visualized 
using a biotinylated rabbit anti-goat antibody (Sigma Aldrich 
Co., St. Louis, MO, USA). The density of the bands obtained was 
measured using a Bio-Rad GS-800 densitometer. The amount of 
cleaved HK was expressed as a percentage of total HK.
Pla2 activity assay
Activity of PLA2 in plasma of patients and healthy controls was 
measured by Life Technologies EnzChek®phospholipase A2 
assay. Briefly, a PLA2 substrate cocktail consisting of 7-hydrox-
ycoumarinyl-arachidonate (0.3  mM), 7-hydroxycoumarinyl- 
linolenate (0.3 mM), hydroxycoumarinyl 6-heptenoate (0.3 mM), 
dioleoylphosphatidylcholine (DOPC) (10  mM), and diole-
oylphosphatidylglycerol (DOPG) (10  mM) was prepared in 
ethanol. Liposomes were formed by gradually adding 77 µl sub-
strate/lipid cocktail to 10 ml of PLA2 buffer (50 mM Tris–HCl, 
100 mM NaCl, 1 mM CaCl2) while stirring rapidly over 1 min 
using a magnetic stirrer Fluorescence (excitation at 360 nm and 
emission at 460 nm) was measured and specific activity [relative 
fluorescent units (RFU)/ml] for each sample was calculated. 
Plasma (50  µl) of patients and healthy controls was added to 
96-well plates, and PLA2 activity was evaluated by adding 
50  µl of substrate cocktail. In selected experiments, plasma of 
patients with C1-INH-HAE was incubated (20 min, 37°C) with 
Me-Indoxam (100  nM) and RO032107A (100  nM) or control 
medium. At the end of incubation, PLA2 activity was measured.
elisa for hgiia
Human sPLA2 group IIA levels in plasma samples were determined 
by ELISA kit (Catalog No. MBS9303777, MyBioSource, San Diego, 
CA, USA). The concentration of hGIIA in plasma was tested in 
duplicate and determined against a standard curve for each ELISA 
FigUre 1 | Plasma levels sPLA2 activity and hGIIA protein in symptom-free with C1-INH-HAE patients and healthy controls. Data are shown as the median 
(horizontal black line), the 25th and 75th percentiles (boxes) and the 5th and 95th percentiles (whiskers) of 68 healthy controls and 109 C1-INH-HAE patients for 
sPLA2 (a) and 36 controls and patients for hGIIA assessment (B). Correlation between sPLA2 and hGIIA (c) was assessed by Spearman’s correlation analysis and 
reported as coefficient of correlation (r). (D) Plasma of patients with C1-INH-HAE (black circles) and of healthy controls (white circles) was pre-incubated (20 min, 
37°C) with Me-Indoxam (100 nM), RO032107A (100 nM), or control medium. At the end of incubation, sPLA2 activity was evaluated.
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assay. To evaluate the reliability of the assay we loaded 500 and 
1,000  pg/ml of recombinant hGIIA in the ELISA wells and the 
spectrophotometer measured 397 and 886 pg/ml, respectively.
In Vitro Vascular Permeability assay
Endothelial cell permeability was assessed by in  vitro vascular 
permeability assay kit (Life Technologies, Carlsbad, CA, USA). 
BEAC were seeded onto collagen-coated Transwell filters (1 µm 
pore size) at the density of 7.5 × 104 cells/well in a 96-well receiver 
plate and incubated at 37°C and 5% CO2 for 72 h. After this time, 
cells starvation step was performed by adding DMEM 0.5% 
FBS and incubation for 18  h at 37°C, 5% CO2. Plasma from 
patients with C1-INH-HAE was pre-incubated (20  min, 37°C) 
with Me-Indoxam (100 nM), RO032107A (100 nM), anti-VEGF-
A (1 µg/ml), anti-Ang2 (1 µg/ml), anti-Ang1 (1 µg/ml), or control 
medium. BAEC were then pre-incubated (30  min, 37°C) with 
heparinase (0.4 U/ml) or control medium and then stimulated 
(18  h, 37°C) with plasma of healthy controls, or with plasma 
of C1-INH-HAE patients or with the combination of C1-INH-
HAE plasma with Me-Indoxam, RO032107A, anti-VEGF-A, 
anti-Ang2, and anti-Ang1. To evaluate vascular permeability, a 
high-molecular weight FITC-Dextran was added on top of the 
cells, allowing the fluorescent molecules to pass through the 
endothelial cell monolayer at a rate proportional to the mon-
olayer’s permeability. The extent of permeability was determined 
by measuring the fluorescence (485 nm excitation and 535 nm 
emission) using Sunrise™ spectrofluorometer (Tecan) and RFU 
was calculated.
statistical analysis
Data were analyzed with the GraphPad Prism 5 software package. 
Data were tested for normality using the D’Agostino–Pearson 
normality test. If normality was not rejected at 0.05 significance 
level, we used parametric tests. Otherwise, for not-normally 
distributed data we used nonparametric tests. Statistical analy-
sis was performed by unpaired two-tailed t-test or two-tailed 
Mann–Whitney test as indicated in figure legends. Correlations 
between two variables were assessed by Spearman’s correlation 
analysis and reported as coefficient of correlation (r). Plasma 
activity of sPLA2 and hGIIA is shown as the median (horizontal 
black line), the 25th and 75th percentiles (boxes) and the 5th and 
95th percentiles (whiskers) of 68 controls and 109 patients. In 
selected experiments, the data are expressed as mean values ± SD 
of the indicated number of experiments. Statistical analysis was 
performed with Prism 5 (GraphPad Software) by one-way analy-
sis of variance followed by Dunnett’s test (when comparison was 
made against a control). Statistically significant differences were 
accepted when the p value was ≤0.05.
resUlTs
increased Plasma levels of sPla2 
enzymatic activity and hgiia Protein  
in Patients with c1-inh-hae  
compared with healthy controls
We assessed the PLA2 enzymatic activity (likely attributable to 
sPLA2) in the plasma from 109 C1-INH-HAE patients in the 
symptom-free period vs 68 healthy controls matched for age 
and gender (Table 1). Figure 1A shows that sPLA2 activity was 
increased by appreciatively twofold in C1-INH-HAE patients 
in symptom-free period compared with controls [sPLA2: 2.4 
(1.3–3.0) vs 1.3 (0.6–1.8) U/ml median values (interquartile 
ranges)]. No gender or age differences in sPLA2 activity were 
found in both controls and patients and (see Table S1 and Figure 
S1 in Supplementary Material).
Several sPLA2s have been identified in mammals (IB, IIA, IIC, 
IID, IIE, IIF, III, V, X, XIIA, XIIB, and otoconin-95) (27), with 
hGIIA being the most represented in human serum and plasma 
(43–47). Accordingly, we found increased levels of hGIIA protein 
in C1-INH-HAE patients compared with controls (Figure 1B). 
The sPLA2 enzymatic activity in plasma from C1-INH-HAE 
patients strongly correlated with hGIIA plasma levels (r = 0.77; 
p < 0.01) (Figure 1C). The enzymatic activity was significantly 
inhibited by Me-Indoxam (an enzymatic inhibitor of several 
sPLA2s) (38) and RO032107A (a specific hGIIA inhibitor) (39) 
in both C1-INH-HAE patients and healthy donors (Figure 1D). 
Collectively, these results indicate that the increased sPLA2 
FigUre 3 | Correlations between sPLA2 activity and cleaved HK, VEGF-A, VEGF-C, and Angs concentrations. Correlations between two variables: sPLA2 (U/ml) 
and cleaved HK (a), sPLA2 and VEGF-A (B), sPLA2 and VEGF-C (c), sPLA2 and Ang1 (D), and sPLA2 and Ang2 (e), were assessed by Spearman’s correlation 
analysis and reported as coefficient of correlation (r).
FigUre 2 | Correlations between sPLA2 activity and complement components. sPLA2 activity in patients with different functional activity of C1-INH. (a) Correlation 
between sPLA2 and C1-INH activity was assessed by Spearman’s correlation analysis and reported as coefficient of correlation (r). (B) Patients were divided in two 
groups: C1-INH type I patients with less than 25 or 25–50% of normal C1-INH protein values. (c) Patients were divided in two groups: C1-INH-HAE patients with 
less than 25 or 25–50% of normal C4 values. Activity of sPLA2 (B,c) is shown.
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enzymatic activity observed in the plasma from C1-INH-HAE 
patients is likely attributable to higher levels of hGIIA protein.
The sPla2 activity in Plasma inversely 
correlates with c1-inh Functional activity 
and Protein levels
In C1-INH-HAE patients, functional C1-INH levels are, by defi-
nition, below 50% of the normal value (40) and C4 concentrations 
are usually reduced and can be used as a screening test (48). 
We investigated whether differences in the complement compo-
nent levels (C1-INH and C4) were associated with differences in 
sPLA2 activity. C1-INH activity negatively correlated with sPLA2 
activity (r = −0.29; p < 0.01) (Figure 2A). Moreover, C1-INH-
HAE type I patients with lower C1-INH protein concentration 
(less than 25% of normal values) had higher plasma activity of 
sPLA2s than patients with higher C1-INH protein concentration 
(25–50% of normal values) [2.6 (1.8–3.0) vs 2.2 (1.4–2.7) U/ml] 
(Figure  2B). When we stratified the patients according to the 
concentration of C4 (less than 25 or 25–50% of normal values) 
no difference in sPLA2 plasma activity between these groups was 
found (Figure 2C).
We have previously demonstrated that in C1-INH-HAE 
patients in symptom-free period plasma concentrations of cleaved 
HK (8) and vascular permeability factors (i.e., VEGFs and Angs) 
are increased compared with healthy controls (17). Interestingly, 
sPLA2 activity did not correlate with cleaved HK (Figure  3A), 
VEGF-A (Figure 3B), VEGF-C (Figure 3C), and Ang1 (Figure 3D) 
concentrations. sPLA2 inversely correlated with Ang2 concentra-
tions (r = −0.20; p < 0.05) (Figure 3E).
lack of association between sPla2 
activity in Plasma and angioedema 
attacks
To investigate a possible role for sPLA2s in angioedema attacks, 
we measured its activity in patients with less (low frequency) 
or more than 12 attacks (high frequency) in the last 12 months. 
sPLA2 activity was comparable in these two groups (Figure 4A). 
In addition, we compared sPLA2 activity in 22 C1-INH-HAE 
patients in symptom-free period and during angioedema 
attacks. We found that the sPLA2 activity [attack 1.2 (0.4–2) 
vs symptom-free period 3.0 (1.4–4.4) U/ml] was reduced in 
patients examined during attack compared with basal condi-
tions (Figure 4B).
hgiia activity in c1-inh-hae Plasma 
increases endothelial Permeability
Secreted phospholipases A2 can modulate endothelial cell 
mobility and vascular permeability (36). To gain mechanistic 
insight into the role of sPLA2s in C1-INH-HAE, we performed 
FigUre 6 | Effect of hGIIA on C1-INH activity. Plasma from normal donors 
was incubated (2 h, 37°C) with increasing concentrations (0.5–5 µg/ml) of 
hGIIA or with medium alone and then functional activity of C1-INH was 
evaluated by colorimetric assay. Data are expressed as percent inhibition of 
the maximum plasma activity of C1-INH calculated as (R − Rb) × 100, where 
R is the C1-INH activity in plasma samples treated with the hGIIA, Rb is the 
C1-INH activity in unstimulated samples. Data are the mean ± SD of 15 
experiments.
FigUre 5 | In vitro effects of plasma from healthy controls or patients with 
C1-INH-HAE on vascular permeability. (a) Bovine aortic endothelial cells 
(BAEC) were incubated (18 h, 37°C) with plasma from healthy controls  
or from symptom-free patients with C1-INH-HAE. The in vitro vascular 
permeability was assessed as indicated in Section “Materials and Methods.” 
(B) Plasma of patients with C1-INH-HAE was incubated (20 min, 37°C) with 
anti-VEGF-A (1 µg/ml), anti-Ang2 (1 µg/ml), anti-Ang1 (1 µg/ml), Me-Indoxam 
(100 nM), RO032107A (100 nM), or control medium. BAEC were then 
pre-incubated (30 min, 37°C) with heparinase (0.4 U/ml) or control medium 
and stimulated (18 h, 37°C) with plasma of C1-INH-HAE patients alone or 
with the combination of C1-INH-HAE plasma with inhibitors and then we 
evaluated vascular permeability. Data are shown in relative fluorescence  
units. *p Value ≤0.05 and **p value ≤0.01 vs untreated plasma.
FigUre 4 | Relationships between sPLA2 activity and angioedema attacks. 
(a) sPLA2 activity was determined in 69 patients with low frequency (<12/
year) and 40 patients with high frequency (>12/year). (B) sPLA2 activity in 
plasma collected from 22 patients with C1-INH-HAE patients during 
symptom-free period (Basal) and during acute attack (Attack).
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an in vitro vascular permeability assay by monitoring the leak-
age of dextran-FITC through a tight monolayer of BAEC (49). 
Interestingly, plasma from angioedema patients in symptom-free 
period increased endothelial permeability compared with con-
trol plasma from healthy donors [128 (95–207) vs 52 (8.5–125) 
RFU] (Figure 5A). To assess whether sPLA2 activity in plasma 
was responsible for this phenomenon, we incubated C1-INH-
HAE plasma with blocking antibodies against VEGF-A, Ang1, 
and Ang2 or Me-Indoxam and RO032107A. Anti-VEGF-A and 
anti-Ang2 but not anti-Ang1 reduced the effect of C1-INH-
HAE plasma without completely abolishing it (i.e., permeability 
levels were still higher compared with healthy donor plasma) 
(Figure  5B). Interestingly, Me-Indoxam and RO032107A also 
reduced vascular permeability induced by C1-INH-HAE plasma 
(Figure  5B) [untreated: 145 (126–227) vs Me-Indoxam 91 
(34–114) RFU]. sPLA2s also bind to HSPGs that may mediate 
some of their biological effects (50–52). To evaluate a possible 
role for HSPGs, BAEC were treated with heparinase to eliminate 
surface HSPGs before stimulation with plasma (23). Heparinase 
treatment of BAEC reduced the endothelial permeability induced 
by C1-INH-HAE plasma [untreated: 145 (126–227) vs hepari-
nase 117 (92–132) RFU] to a level comparable to Me-Indoxam 
and RO032107A (Figure 5B).
hgiia impairs c1-inh Functional activity
Our results demonstrate that hGIIA activity in C1-INH-HAE 
plasma increases endothelial leakage in  vitro, supporting a 
mecha nistic role for sPLA2s in modulating vascular permeability 
in vivo (i.e., C1-INH-HAE patients). This effect can be mediated 
by a direct modulation of endothelial cells through enzymatic 
activity and/or receptor-mediated mechanisms (e.g., binding to 
HSPGs). Nevertheless, we hypothesized that hGIIA could also 
directly affect C1-INH activity. To this aim, we incubated in vitro 
plasma from healthy controls (containing normal C1-INH) with 
recombinant hGIIA and assessed C1-INH functional activ-
ity. Interestingly, hGIIA concentration-dependently reduced 
C1-INH activity (Figure 6).
DiscUssiOn
In this study, we found that plasma sPLA2 enzymatic activity and 
hGIIA are increased in symptom-free C1-INH-HAE patients 
compared with healthy controls. sPLA2 activity is positively corre-
lated with hGIIA plasma concentrations and inversely correlated 
with C1-INH activity and protein level. hGIIA in C1-INH-HAE 
plasma increases endothelial permeability and hGIIA impairs 
C1-INH functional activity in  vitro. No correlation was found 
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between plasma sPLA2 activity and the severity of angioedema 
and intriguingly sPLA2 activity was decreased during attacks.
The local generation of BK causes angioedema in C1-INH 
deficiency (10). It is well established that this mediator comes 
from HK and is cleaved by plasma kallikrein lacking its main 
physiological inhibitor (11). It is still unclear whether BK gen-
eration is sufficient to cause an angioedema attack or if other 
mechanisms are involved. We have demonstrated that plasma 
levels of vascular permeability factors (i.e., VEGFs and Angs) 
are increased in symptom-free C1-INH-HAE patients (17). 
In this study, we demonstrate that sPLA2 activity is increased 
in plasma of C1-INH-HAE patients and negatively correlates 
with C1-INH plasma activity. Although multiple sPLA2s have 
been described in mammals, several lines of evidence support 
a specific role for hGIIA in C1-INH-HAE. First, hGIIA is the 
most represented sPLA2 in human serum and plasma (43–47). 
Second, hGIIA plasma levels are increased in C1-INH-HAE 
patients compared with healthy controls. Moreover, hGIIA 
plasma levels strongly correlates with C1-INH activity. Finally, 
sPLA2 activity in the plasma from both C1-INH-HAE patients 
and healthy controls is markedly reduced by the hGIIA-specific 
enzymatic inhibitor RO032107A (39).
Our results suggest a possible involvement of hGIIA in the 
pathogenesis of C1-INH-HAE. We show that plasma from 
C1-INH-HAE patients increases endothelial permeability in vitro 
compared with healthy donor plasma. Their effect is partially 
reverted by the addition of the hGIIA-specific enzymatic inhibi-
tor RO032107A or endothelial cell treatment with heparinase, 
an enzyme that degrades HSPGs. It is conceivable that hGIIA 
in C1-INH-HAE plasma binds to HSPGs on endothelial surface 
and increases endothelial cell permeability in a process that 
requires its enzymatic activity. These results are in keeping with 
the evidence that sPLA2s can modulate endothelial cell perme-
ability directly or through the release of vasoactive mediators 
(e.g., PGE2, VEGFs, and Angs) (17, 18, 31). Further studies are 
required to gain more insights into this model and define its 
relevance to C1-INH-HAE pathogenesis.
We also uncovered another possible mechanism of hGIIA 
involvement in C1-INH-HAE pathophysiology that is inde-
pendent of its interaction with endothelial cells. We found 
that hGIIA impairs C1-INH activity of healthy donor plasma 
in a concentration-dependent manner. Modulation of C1-INH 
by other classes of enzymes has already been demonstrated. 
For example, the proteases elastase and plasmin degrade 
C1-INH (53, 54). C1-INH also interacts with MBL-associated 
serine protease 1 (MASP-1), and C1-INH/MASP-1 complexes 
are reduced in C1-INH-HAE patients (55). Interestingly, both 
wild-type and catalytically inactive hGIIA bind to factor Xa 
of the coagulation cascade and inhibit prothrombinase acti-
vity (56). Whether hGIIA interacts with C1-INH in vitro and 
in vivo, and whether hGIIA enzymatic activity is required for 
impairing C1-INH activity require further investigation. Our 
plane is to study a potential interaction between C1-INH and 
hGIIA, thermodynamically and kinetically, employing single-
molecule in vitro assays (e.g., surface plasmon resonance and 
isothermal titration calorimetry). Furthermore, at a later 
time, it could be possible to detect this interaction on plasma 
samples.
It has been suggested that a systemic activation process can 
occur in patients with HAE (4). Accordingly, we have hypothe sized 
that C1-INH deficiency and inflammatory stimuli contribute to 
generate a variable, ongoing increase in vascular permeability 
that defines the threshold where localized triggers act for the 
development of angioedema attack (17). This hypothesis is also 
supported by previous findings indicating that several proin-
flammatory mediators such as C reactive protein (57, 58) and 
pentraxin 3 (57) are elevated in asymptomatic C1-INH-HAE 
patients and during attacks. Moreover, VEGFs (17) and sPLA2 
produced by activated immune cells (29, 31, 59–61) are elevated 
in C1-INH-HAE patients. Together, these findings suggest that 
low-grade systemic inflammation can occur in these patients.
Comprehensive studies have identified BK as the principal 
mediator of vascular leakage in C1-INH-HAE-related swelling 
attacks (10, 62) Circulating levels of BK, markers of endothelial 
activation, prothrombin fragments, D-dimer (63), cytokines 
(e.g., TNF-α and IL-8), as well as neutrophil count and neutro-
phil-derived factors (e.g., elastase, myeloperoxidase, pentraxin 3) 
(64) are increased during attacks compared with symptom-free 
periods in C1-INH-HAE patients. By contrast, we found that 
sPLA2 activity is consistently decreased during attacks and does 
not correlate with canonical biomarkers of angioedema severity 
(i.e., cleaved HK) (65). Whatever the mechanism(s), sPLA2 
is the first mediators so far identified which shows opposite 
beha vior during clinical remission (i.e., increase) and angi-
oedema attacks (i.e., reduction). The reasons for this intriguing 
observation are unclear and command additional in vitro and 
in vivo investigations. Furthermore, our preliminary data show 
that sPLA2 activity is not modified by prophylactic treatments 
(either tranexamic acid or attenuated androgens) compared with 
untreated patients (unpublished results).
In conclusion, our study provides evidence for a possible 
role of hGIIA in the pathophysiology of C1-INH-HAE and also 
gives mechanistic insights into how hGIIA may predispose to the 
development of angioedema attacks.
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